The Kehn-Hall lab has been focusing heavily on the study of host-pathogen interactions of Rift Valley fever virus (RVFV). Recently, they demonstrated that the cellular antioxidant enzyme superoxide dismutase 1 (SOD1) is down regulated at early time points following exposure to RVFV. They provided evidence for extensive oxidative stress in RVFV infected cells. Concomitantly, there was an increase in the activation of the p38 MAPK stress response, which was regulated by the viral anti-apoptotic protein NSm. Alterations in the host protein SOD1 following RVFV infection appears to be an early event that occurs in multiple cell types. These data implies that maintaining oxidative homeostasis in the infected cells may play an important role in improving survival of infected cells. (Narayanan et al., Alteration in superoxide dismutase 1 causes oxidative stress and p38 MAPK activation following RVFV infection. 2011, PLoS One.6(5):e20354).
BRCA1 is a multifaceted tumor suppressor protein that has implications in processes such as cell cycle, transcription, DNA damage response and chromatin remodeling. The Kehn-Hall lab has demonstrated for the first time that BRCA1 is methylated both in breast cancer cell lines and breast cancer tumor samples at arginine and lysine residues. Arginine methylation by PRMT1 was observed in vitro and the region of BRCA1 504-802 shown to be highly methylated and the site of interaction. Inhibition of methylation resulted in decreased BRCA1 methylation and alteration of BRCA1 binding to promoters in vivo. Following methylation inhibition, Sp1 was found to preferentially associate with hypo-methylated BRCA1 and STAT1 was found to preferentially associate with hyper-methylated BRCA1. These results suggest that methylation may influence either the ability of BRCA1 to bind to specific promoters or protein-protein interactions which alters the recruitment of BRCA1 to these promoters. Thus, given the importance of BRCA1 to genomic stability, methylation of BRCA1 may ultimately affect the tumor suppressor ability of BRCA1. (Guendel et al. Methylation of the tumor suppressor protein, BRCA1, influences its transcriptional cofactor function. PLoS One. 2010 Jun 29;5(6):e11379).
As part of a continued search for more efficient anti-HIV-1 drugs, the Kehn-Hall lab is focusing on small molecule inhibitors that can efficiently inhibit HIV-1 replication through the restoration of p53 and p21WAF1 functions, which are inactivated by HIV-1 infection. They demonstrated that 9-aminoacridine (9AA) treatment inhibits HIV LTR transcription in a specific manner that was highly dependent on the presence and location of the amino moiety. Importantly, virus replication was found to be inhibited by 9AA in a dose-dependent manner without inhibiting cellular proliferation or inducing cell death. 9AA inhibited viral replication in both p53 wildtype and p53 mutant cells, indicating that there is another p53 independent factor that was critical for HIV inhibition. Furthermore, p21WAF1 was observed in complex with cyclin T1 and cdk9 in vitro, suggesting a direct role of p21WAF1 in HIV transcription inhibition. Finally, 9AA treatment resulted in loss of cdk9 from the viral promoter, providing one possible mechanism of transcriptional inhibition. Thus, 9AA treatment was highly efficient at reactivating the p53 – p21WAF1 pathway and consequently inhibiting HIV replication and transcription. (Guendel et al., 9-Aminoacridine inhibition of HIV-1 Tat dependent transcription. Virol J. 2009 Jul 24;6:114).
Some of the latest funding received for the Kehn-Hall lab:
- Ceres Nanosciences, in collaboration with Dr. Kehn-Hall’s Laboratory at GMU NCBID, has been awarded $250,000 from the National Center for Foreign Animal and Zoonotic Disease Defense (FAZD) to develop a transformative technology platform to address the need for the improved detection of Rift Valley Fever Virus (RVFV) and other foreign and zoonotic diseases.
- Dr. Kehn-Hall has been awarded a Commonwealth Health Research Board grant for $200,000 over a 2 year period entitled “BTK induction by HIV: implications for therapeutics”. This project is aimed at understanding the therapeutic potential of targeting Bruton’s Tyrosine Kinase (BTK) in HIV-1 infected cells. Studying BTK could potentially lead to new treatment options for HIV/AIDS.
- Dr. Kehn-Hall has been awarded an Inova/GMU grant for $50,000 over a 2 year period entitled “MicroRNA as Novel Biomarkers in Long Term Non-Progressor HIV-1 Patients”. This work performed in collaboration with Dr. Donald Poretz is aimed at the identification of microRNAs that are uniquely expressed in HIV LTNP patients, who have naturally immunity to HIV.